Article
Identification immune response genes in psoriasis after treatment with secukinumab
7 Apr 2023
Abstract excerpt
BACKGROUND: Secukinumab is a fully human IgG1κ MoAb that selectively binds to IL-17A with high affinity, and it has been proven effective for the treatment of psoriasis. However, the immune response pathways and mechanisms during the treatment are still masked. Therefore, the current study was designed to investigate the potential immune response genes via bioinformatics approaches. METHODS: Gene expression data...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
